RE:RE:Activate Rutherrin(R) At HomeLegit62 wrote: Freaken brilliant, $100 a share in the making
A "reduction in the risk of" ??? Hmmm... ------------------------------------------------------------ August 22, 2024 --------------------------------- Health Canada Approves KEYTRUDA for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination with enfortumab vedotin-------------------------------------------------- "The trial demonstrated a 53% reduction in the risk of death with P+EV (HR=0.47 [95% CI, 0.38-0.58]; p<0.0001) versus platinum-based chemotherapy; the median os was 31.5 months (95% ci, 25.4, nr) for the p+ev combination versus 16.1 months (95% ci, 13.9, 18.3) for platinum-based chemotherapy. there was also a statistically significant improvement in pfs and orr in patients randomized to pembrolizumab in combination with enfortumab vedotin compared to the control arm." --------------------------------------- https://www.biospace.com/health-canada-approves-keytruda-for-the-treatment-of-adult-patients-with-unresectable-locally-advanced-or-metastatic-urothelial-cancer-muc-with-no-prior-systemic-therapy-for-muc-in-combination-with-enfortumab-vedotin versus="" platinum-based="" chemotherapy;="" the="" median="" os="" was="" 31.5="" months="" (95%="" ci,="" 25.4,="" nr)="" for="" the="" p+ev="" combination="" versus="" 16.1="" months="" (95%="" ci,="" 13.9,="" 18.3)="" for="" platinum-based="" chemotherapy.="" there="" was="" also="" a="" statistically="" significant="" improvement="" in="" pfs="" and="" orr="" in="" patients="" randomized="" to="" pembrolizumab="" in="" combination="" with="" enfortumab="" vedotin="" compared="" to="" the="" control="" arm."="" ---------------------------------------="">